Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIGHT-Child TB
NCT07893444Phase 2Recruiting
- Sponsor
- Huashan Hospital
- Start
- Jul 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bedaquiline, delamanid and contezolid in Tuberculosis (TB) (3 arms), sponsored by Huashan Hospital. Primary endpoints: Tuberculosis-free survival at 12 months and Incidence of grade 3 or higher adverse events at 6 months. Started Jul 2026; status: recruiting.
02
Drugs
bedaquilinedelamanidcontezolid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07893444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07893444.